Evidence map›Paper›PMID 26056449›Full record

ArticleInternational journal of nanomedicine2015

Efficacy and mechanism of tanshinone IIA liquid nanoparticles in preventing experimental postoperative peritoneal adhesions in vivo and in vitro.

Fei Qin, Yun Ma, Xiao Li, Xian Wang, Yuanyi Wei, Chuqi Hou, Si Lin, Lianbing Hou, Chengxi Wang

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Application of Traditional Chinese Medicines in Postoperative Abdominal Adhesion.Evidence-based complementary and alternative medicine : eCAM · 2020
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Fei QinDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Yun MaDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Xiao LiDepartment of Pharmacy, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China.
Xian WangDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Yuanyi WeiDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Chuqi HouDepartment of Pharmacology, Southern Medical University, Guangzhou, People's Republic of China.
Si LinDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Lianbing HouDepartment of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Chengxi WangDepartment of Pharmacology, Guangdong Pharmaceutical University, Guangzhou, People's Republic of China.
Southern Medical University · CNNanfang Hospital · CNGuangdong Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Up to 90% of patients develop adhesion following laparotomy. Upregulating fibrinolysis within the peritoneum reduces adhesions. Tanshinone IIA (Tan IIA) promotes fibrinolysis in hepatic fibrosis and the cardiovascular system and may play a role in preventing adhesions. We report preparation and characterization of liquid nanoparticles of Tan IIA for intravenous administration and investigate its feasibility in clinical practice. Tan IIA liquid nanoparticles (Tan IIA-NPs) were prepared using the emulsion/solvent evaporation method. Adhesions were induced in Sprague-Dawley rats by injuring the parietal peritoneum and cecum, followed by intravenous administration of various Tan IIA-NP dosages. The adhesion scores for each group were collected 7 days after the initial laparotomy. The activity of tissue-type plasminogen activator (tPA) was measured from the peritoneal lavage fluid. The messenger RNA and protein expression levels of plasminogen activator inhibitor-1 (PAI-1) were measured by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay. TGF-β1 and collagen I expressions were measured immunohistochemically in the ischemic tissues. The effects of Tan IIA-NPs and free-Tan IIA on tPA and PAI-1 were measured in vitro in TGF-β1-induced HMrSV5 cells. Tan IIA-NPs exhibited small particle size, high encapsulation efficiency, good stability for storage, and safety for intravenous administration. Tan IIA-NPs were effective in preventing adhesion. Tan IIA-NPs increased tPA activity in peritoneal lavage fluid, and tPA mRNA and protein expression, and decreased PAI-1 mRNA and protein expression in the ischemic tissues. Moreover, Tan IIA-NPs decreased TGF-β1 and collagen I expressions in the ischemic tissues. Tan IIA-NPs administered via tail veins upregulated fibrinolysis in the peritoneum. In vitro studies showed that these effects may be mediated by the TGF-β signal pathway.

Indexed as

AbietanesAdministration, IntravenousAnimalsEnzyme-Linked Immunosorbent AssayFibrinolysisMaleMice, Inbred BALB CNanoparticlesPeritoneal DiseasesPlasminogen Activator Inhibitor 1Postoperative ComplicationsRats, Sprague-DawleyReal-Time Polymerase Chain ReactionTissue AdhesionsTissue Plasminogen ActivatorTransforming Growth Factor beta1AbietanesPlasminogen Activator Inhibitor 1tanshinoneTissue Plasminogen ActivatorTransforming Growth Factor beta1peritoneal fibrinolysisplasminogen activator inhibitor-1tissue-type plasminogen activator

Identifiers

PMID26056449
PMCPMC4445949
OpenAlexW1779235981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.